Press Releases Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Market Closed - Nasdaq Stockholm Other stock markets 11:29:34 2024-05-27 am EDT			5-day change	1st Jan Change
113.6 ^SEK	-0.79%		-3.07%	-10.62%

May. 24	HC Wainwright Cuts Calliditas Therapeutics Price Target to $45 From $50, Maintains Buy Rating	MT
May. 23	Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Presentation)	May. 23	PU
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Report)	May. 23	PU
Calliditas Q1 report, January - March 2024	May. 23	AQ
In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	May. 16	PU
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	May. 16	AQ
Calliditas Therapeutics : Invitation to the presentation of Calliditas´s interim report January - March 2024	May. 16	PU
Invitation to the presentation of Calliditas's interim report January - March 2024	May. 16	AQ
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm	May. 15	AQ
Notice of annual general meeting of Calliditas Therapeutics AB (publ)	May. 15	AQ
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China	May. 14	AQ
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	May. 06	AQ
Calliditas Therapeutics' 2023 Annual Report Published	Apr. 24	AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results	Apr. 24	AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	AQ
Calliditas Therapeutics to Attend Conferences in April	Apr. 09	AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires	Apr. 08	AQ
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment	Apr. 08	AQ
Calliditas Therapeutics : February 21, 2024 Year-end report 2023 (Presentation)	Mar. 14	PU
Calliditas announces an additional seven year orphan drug exclusivity Period for TARPEYO	Mar. 07	AQ
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®	Mar. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Press Releases

Filters